Trial Review

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/ct2/show/NCT05824585




Registration number
NCT05824585
Ethics application status
Date submitted
30/03/2023
Date registered
21/04/2023
Date last updated
21/04/2023

Titles & IDs
Public title
DZD8586 in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
Scientific title
A Phase 1, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Efficacy of DZD8586 in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (B-NHL)
Secondary ID [1] 0 0
DZ2022B0002
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Lymphoma, Non-Hodgkin 0 0
Condition category
Condition code
Cancer 0 0 0 0
Lymphoma (non Hodgkin's lymphoma) - High grade lymphoma
Cancer 0 0 0 0
Lymphoma (non Hodgkin's lymphoma) - Low grade lymphoma

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - DZD8586

Experimental: DZD8586 -


Treatment: Drugs: DZD8586
DZD8586 treatment starting from 50 mg once daily. If tolerated, subsequent cohorts will test increasing doses of DZD8586.
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Part A: Incidence of adverse events
Timepoint [1] 0 0
30 days after the last dose, assessed up to 2 years
Primary outcome [2] 0 0
Part B: Objective Response Rate assessed by investigators
Timepoint [2] 0 0
assessed up to 2 years
Secondary outcome [1] 0 0
Part A: Objective Response Rate assessed by investigators
Timepoint [1] 0 0
assessed up to 2 years
Secondary outcome [2] 0 0
Part A: Plasma and CSF concentration of DZD8586
Timepoint [2] 0 0
through discontinuation of treatment up to 10 weeks
Secondary outcome [3] 0 0
Part B: Duration of Response assessed by investigators
Timepoint [3] 0 0
from date of first documented response until the date of documented progression, assessed up to 2 years
Secondary outcome [4] 0 0
Part B: Incidence of adverse events
Timepoint [4] 0 0
30 days after the last dose, assessed up to 2 years
Secondary outcome [5] 0 0
Part B: Plasma and CSF concentration of DZD8586
Timepoint [5] 0 0
through discontinuation of treatment, assessed up to 2 years

Eligibility
Key inclusion criteria
1. Male or female participants who have provided ICF with age = 18 yrs

2. ECOG performance 0-2, no deterioration in the past 2 weeks

3. Participants with relapsed or refractory B-NHL must have cytologically or
histologically confirmed B-cell lymphoma

4. Adequate bone marrow reserve and organ system functions

5. Participants willing to comply with contraceptive restrictions
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
1. Any unresolved > Grade 1 adverse event at the time of starting study treatment with
the exception of alopecia.

2. Prior history of allogeneic hematopoietic stem cell transplantation

3. Stem cell transplantation, cell therapy, or gene therapy within 90 days. Approved
small molecule therapy within 5 half-lives, investigational small molecule therapy
within 14 days. Monoclonal antibodies and antibody-drug conjugates within 28 days
Radiation therapy within 1 weeks

4. Live attenuated vaccines or viral vector vaccines within 4 weeks. Major surgery or
significant traumatic injury within 4 weeks. History of stroke or intracranial
hemorrhage within 6 months

5. Participants with non-CNSL presence of CNS or intraocular lymphoma lesions.

6. CNSL participants with systemic presence of lymphoma, unable to complete lumbar
puncture, under systemic corticosteroids at a dose > 8 mg/day (dexamethasone
equivalent dose) within 14 days or requiring immunosuppressive or biologic therapy."

7. Participants with infectious disease:

8. Clinically significant cardiac disorders or abnormalities

9. Another malignancy within 5 years prior to enrollment with the exception of adequately
treated in-situ carcinoma of the cervix, uterus, basal or squamous cell carcinoma or
non-melanomatous skin cancer.

10. Refractory nausea and vomiting if not controlled by supportive therapy, chronic
gastrointestinal diseases, inability to swallow the formulated product or previous
significant bowel resection that would preclude adequate absorption

11. Women who are breast feeding

12. Psychological, familial, sociological, or geographical conditions that do not permit
compliance with the protocol

Study design
Purpose of the study
Treatment
Allocation to intervention
N/A
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Other
Other design features
Phase
Phase 1
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Not yet recruiting
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
1/04/2023
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
30/10/2027
Actual
Sample size
Target
20
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
WA
Recruitment hospital [1] 0 0
Linear Clinical Research Ltd - Perth
Recruitment postcode(s) [1] 0 0
6009 - Perth

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
Dizal Pharmaceuticals
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
This study will treat patients with B-NHL who have relapsed, progressed, or were intolerant
to systemic therapy progressed following prior therapy. This study will help to understand
what type of side effects may occur with the drug treatment. It will also measure the levels
of drug in the body and assess its anti-cancer activity as monotherapy.
Trial website
https://clinicaltrials.gov/ct2/show/NCT05824585
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Liu
Address 0 0
Dizal Pharma
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Ziyi Liu
Address 0 0
Country 0 0
Phone 0 0
+86 021 6109 5852
Fax 0 0
Email 0 0
[email protected]
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/ct2/show/NCT05824585